Cargando…

Engineering medicinal plant-derived CYPs: a promising strategy for production of high-valued secondary metabolites

MAIN CONCLUSION: Cytochorme P450s (CYPs) play a critical role in the catalysis of secondary metabolite biosynthetic pathways. For their commercial use, various strategies for metabolic pathway engineering using CYP as a potential target have been explored. ABSTRACT: Plants produce a vast diversity o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sethi, Anshika, Bhandawat, Abhishek, Pati, Pratap Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664027/
https://www.ncbi.nlm.nih.gov/pubmed/36378350
http://dx.doi.org/10.1007/s00425-022-04024-9
_version_ 1784831012624138240
author Sethi, Anshika
Bhandawat, Abhishek
Pati, Pratap Kumar
author_facet Sethi, Anshika
Bhandawat, Abhishek
Pati, Pratap Kumar
author_sort Sethi, Anshika
collection PubMed
description MAIN CONCLUSION: Cytochorme P450s (CYPs) play a critical role in the catalysis of secondary metabolite biosynthetic pathways. For their commercial use, various strategies for metabolic pathway engineering using CYP as a potential target have been explored. ABSTRACT: Plants produce a vast diversity of secondary metabolites which are being used to treat various ailments and diseases. Some of these metabolites are difficult to obtain in large quantities limiting their industrial use. Cytochrome P450 enzymes (CYPs) are important catalysts in the biosynthesis of highly valued secondary metabolites, and are found in all domains of life. With the development of high-throughput sequencing and high-resolution mass spectrometry, new biosynthetic pathways and associated CYPs are being identified. In this review, we present CYPs identified from medicinal plants as a potential game changer in the metabolic engineering of secondary metabolic pathways. We present the achievements made so far in enhancing the production of important bioactivities through pathway engineering, giving some popular examples. At last, current challenges and possible strategies to overcome the limitations associated with CYP engineering to enhance the biosynthesis of target secondary metabolites are also highlighted.
format Online
Article
Text
id pubmed-9664027
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-96640272022-11-14 Engineering medicinal plant-derived CYPs: a promising strategy for production of high-valued secondary metabolites Sethi, Anshika Bhandawat, Abhishek Pati, Pratap Kumar Planta Review MAIN CONCLUSION: Cytochorme P450s (CYPs) play a critical role in the catalysis of secondary metabolite biosynthetic pathways. For their commercial use, various strategies for metabolic pathway engineering using CYP as a potential target have been explored. ABSTRACT: Plants produce a vast diversity of secondary metabolites which are being used to treat various ailments and diseases. Some of these metabolites are difficult to obtain in large quantities limiting their industrial use. Cytochrome P450 enzymes (CYPs) are important catalysts in the biosynthesis of highly valued secondary metabolites, and are found in all domains of life. With the development of high-throughput sequencing and high-resolution mass spectrometry, new biosynthetic pathways and associated CYPs are being identified. In this review, we present CYPs identified from medicinal plants as a potential game changer in the metabolic engineering of secondary metabolic pathways. We present the achievements made so far in enhancing the production of important bioactivities through pathway engineering, giving some popular examples. At last, current challenges and possible strategies to overcome the limitations associated with CYP engineering to enhance the biosynthesis of target secondary metabolites are also highlighted. Springer Berlin Heidelberg 2022-11-15 2022 /pmc/articles/PMC9664027/ /pubmed/36378350 http://dx.doi.org/10.1007/s00425-022-04024-9 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review
Sethi, Anshika
Bhandawat, Abhishek
Pati, Pratap Kumar
Engineering medicinal plant-derived CYPs: a promising strategy for production of high-valued secondary metabolites
title Engineering medicinal plant-derived CYPs: a promising strategy for production of high-valued secondary metabolites
title_full Engineering medicinal plant-derived CYPs: a promising strategy for production of high-valued secondary metabolites
title_fullStr Engineering medicinal plant-derived CYPs: a promising strategy for production of high-valued secondary metabolites
title_full_unstemmed Engineering medicinal plant-derived CYPs: a promising strategy for production of high-valued secondary metabolites
title_short Engineering medicinal plant-derived CYPs: a promising strategy for production of high-valued secondary metabolites
title_sort engineering medicinal plant-derived cyps: a promising strategy for production of high-valued secondary metabolites
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664027/
https://www.ncbi.nlm.nih.gov/pubmed/36378350
http://dx.doi.org/10.1007/s00425-022-04024-9
work_keys_str_mv AT sethianshika engineeringmedicinalplantderivedcypsapromisingstrategyforproductionofhighvaluedsecondarymetabolites
AT bhandawatabhishek engineeringmedicinalplantderivedcypsapromisingstrategyforproductionofhighvaluedsecondarymetabolites
AT patipratapkumar engineeringmedicinalplantderivedcypsapromisingstrategyforproductionofhighvaluedsecondarymetabolites